GSK’s First Lung Cancer Drug Wins FDA Approval: Jideytro Enters Later-Line ROS1-Targeted Treatment Market
For patients with advanced non-small cell lung cancer whose disease continued to worsen after treatment with a ROS1 inhibitor, Jideytro shrank tumors in 44% of patients in a single-arm trial. This approval, completed ahead of schedule, fills a later-line treatment need, but comparative efficacy and long-term safety still require further evidence.